期刊文献+

乳腺浸润癌中HER-2基因扩增与蛋白表达相关性分析 被引量:3

Correlation analysis of HER-2 gene amplification and protein expression in invasive breast cancer
下载PDF
导出
摘要 目的比较分析乳腺浸润癌患者中HER-2蛋白表达与基因扩增的差异性和相关性。方法利用免疫组织化学(IHC)与荧光原位杂交(FISH)技术分别检测乳腺浸润癌患者HER-2蛋白表达和基因扩增情况,并对结果进行相关性分析。结果乳腺浸润癌中HER-2蛋白表达及基因扩增结果具有较好的一致性,总体一致率为91%,IHC结果(+++)中二者结果一致率最高,结果(++)中二者结果一致率最低。结论FISH与IHC两项技术在检测HER-2基因扩增及蛋白表达方面具有较好的一致性。乳腺癌患者应常规进行HER-2的IHC检查,当IHC阳性结果不明确时需进一步行FISH检测HER-2基因的扩增情况,从而为临床综合治疗方案提供更可靠的依据。 Objective Comparative analysis of the differences and correlations between HER-2 protein expression and gene amplification in patients with invasive breast cancer.Methods Immunohistochemistry(IHC)and fluorescence in situ hybridization(FISH)techniques were used to detect the expression of HER-2 protein and gene amplification in patients with invasive breast cancer,and the results were analyzed for correlation.Results HER-2 protein expression was consistent with gene amplification in invasive breast cancer,with 91%overall agreement.The IHC result(+++)showed the highest agreement rate,and the(++)result showed the lowest agreement rate.Conclusion The two technologies,FISH and IHC,have good consistency in detecting the gene amplification and protein expression of the HER-2 gene.HER-2 protein level should be detected by IHC for breast cancer patients.When the results of IHC are not clear,further FISH should be used to detect the amplification of HER-2 gene,so as to provide a more reliable basis for clinical comprehensive treatment programs.
作者 李辉斌 吴坤河 郭玉娟 廖燕霞 陈文静 Li Huibin;Wu Kunhe;Guo Yujuan;Liao Yanxia;Chen Wenjing(Department of Pathology,GuangDong Women and Children Hospital,Guangzhou 511400)
出处 《中国组织化学与细胞化学杂志》 CAS CSCD 2020年第3期250-254,共5页 Chinese Journal of Histochemistry and Cytochemistry
基金 广东省科技计划项目(2017ZC0316)。
关键词 乳腺浸润癌 HER-2 免疫组织化学 荧光原位杂交 Invasive breast cancer HER-2 immunohistochemistry fluorescence in situ hybridization
  • 相关文献

参考文献12

二级参考文献77

  • 1曾瑄,赵大春,周炜洵,武莎斐,梁智勇,刘彤华.荧光原位杂交检测乳腺癌HER2基因状态[J].中华病理学杂志,2005,34(11):701-705. 被引量:65
  • 2王莉萍,沈坤炜,沈镇宙.赫赛汀在乳腺癌新辅助治疗与辅助治疗中的新进展[J].中华肿瘤杂志,2006,28(4):241-243. 被引量:26
  • 3张瑰红,施达仁,梁晓曼,侯景辉,康苏娅,朱卫东,李晓兵,邵云,陈丽荣,周燕.显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J].中华病理学杂志,2006,35(10):580-583. 被引量:29
  • 4<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:163
  • 5Geyer C E, Forster J, Lindquist D, et al. Lapatinib plus capecit- abine for Her-2-positive advanced breast cancer[J]. N Engl J Med, 2006, 355(26):2733-2743.
  • 6Lin A, Rugo H S. The role of trastuzumab in early stage breast eancer: current data and treatment recommendations[J]. Curr Treat Options Oncol, 2007,8(1):47-60.
  • 7Wolff A C, Hammond M E, Schwartz J N, et al. American society of clinical ontology/college of american pathologists guideline recom- mendations for human epidermal growth factor receptor 2 testing in breast cancer[J]. J Clin Oncol, 2007, 25(1):118-145.
  • 8Owens M A, Horten B C, Da Silva M M. Her-2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistoehemistry in a cohort of 6556 breast cancer tissues [J]. Ctin Breast Cancer, 2004, 5(1):63-69.
  • 9Vogel U F. Confirmation of a low Her-2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hy- bridization[J]. Diagn Pathol, 2010, 5(1):50.
  • 10Mass R D, Press M F, Anderson S, et al. Evaluation of clinical outcomes according to Her2 detection by fluorescence in situ hy- bridization in women with metastatic breast cancer treated with trastuzumab[J]. Clin Breast Cancer, 2005,6(3) : 240-246.

共引文献305

同被引文献32

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部